We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Edinburgh Worldwide Investment Trust Plc | LSE:EWI | London | Ordinary Share | GB00BHSRZC82 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
171.80 | 172.00 | 175.00 | 170.00 | 175.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | -181.6M | -182.57M | -0.4867 | -3.53 | 651.98M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:45:01 | O | 50,000 | 171.80 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
12/11/2024 | 15:01 | UK RNS | Edinburgh Worldwide Inv Trust PLC Holding(s) in Company |
12/11/2024 | 11:53 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
11/11/2024 | 15:48 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
11/11/2024 | 10:23 | UK RNS | Edinburgh Worldwide Inv Trust PLC Holding(s) in Company |
08/11/2024 | 15:01 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
07/11/2024 | 15:29 | UK RNS | Edinburgh Worldwide Inv Trust PLC Holding(s) in Company |
07/11/2024 | 12:05 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
06/11/2024 | 18:14 | UK RNS | Edinburgh Worldwide Inv Trust PLC Holding(s) in Company |
06/11/2024 | 11:59 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
05/11/2024 | 11:05 | UK RNS | Edinburgh Worldwide Inv Trust PLC Net Asset Value(s) |
Edinburgh Worldwide Inve... (EWI) Share Charts1 Year Edinburgh Worldwide Inve... Chart |
|
1 Month Edinburgh Worldwide Inve... Chart |
Intraday Edinburgh Worldwide Inve... Chart |
Date | Time | Title | Posts |
---|---|---|---|
08/8/2024 | 16:14 | Edinburgh Worldwide Investment Trust | 76 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
16:45:03 | 171.80 | 50,000 | 85,900.00 | O |
16:35:05 | 171.60 | 71,365 | 122,462.34 | UT |
16:29:57 | 171.80 | 213 | 365.93 | AT |
16:29:57 | 171.80 | 138 | 237.08 | AT |
16:29:57 | 171.80 | 24 | 41.23 | AT |
Top Posts |
---|
Posted at 12/11/2024 08:20 by Edinburgh Worldwide Inve... Daily Update Edinburgh Worldwide Investment Trust Plc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the London Stock Exchange with ticker EWI. The last closing price for Edinburgh Worldwide Inve... was 173.80p.Edinburgh Worldwide Inve... currently has 375,131,908 shares in issue. The market capitalisation of Edinburgh Worldwide Inve... is £644,476,618. Edinburgh Worldwide Inve... has a price to earnings ratio (PE ratio) of -3.53. This morning EWI shares opened at 175p |
Posted at 13/12/2023 11:08 by quepassa Wow.Privately owned SpaceX now valued close to $180 billion in new tender offer at $97 per share. According to trusted Bloomberg today. A significant uplift in SpaceX valuation which should in due course be reflected in both Scottish Mortgage and even more in Edinburgh Worldwide . all imo. dyor. qp |
Posted at 15/6/2023 20:34 by takeiteasy In the COVID tech recovery this shot up and this time around the NASDAQ is well up in 2023 and this part of the market heads ever lower. I looked at some comments today to understand the market conditions better to understand how someone else in this area of the market assessed things. I.e. when we will know there is any sort of recovery to come back in?BIOG trust update today... Macroeconomic factors rather than industry fundamentals continued to dominate portfolio performance during the fiscal year. The fiscal year began with weakness in the biotech sector in April and May 2022, driven by continued investor concerns about rising interest rates. Continued rate hikes by the U.S. Federal Reserve (the Fed) to combat inflation drove down share prices for unprofitable technology stocks broadly, including emerging biotech. Valuations for emerging biotech, which had reached 20-year lows, appeared to bottom out in May and June. In August, drug pricing legislation in the U.S. was passed as part of the Democrats' "Inflation Reduction Act". While the bill allows for limited drug price negotiation by Medicare starting in 2026, the provisions appear manageable for the industry and passage of the bill cleared a longstanding political overhang for the sector. By the end of September, the biotech sector had begun staging a recovery from depressed levels. In October, a disappointing round of earnings from large capitalization (cap) technology stocks like Amazon and Meta and growing recession concerns appeared to draw generalist inflows into the defensive pharmaceutical sector and large cap biotech. Large cap biotech outperformance continued in November, but small cap biotech began outperforming in December, and January 2023. Unfortunately, interest rate expectations became more hawkish in February when the U.S. announced a lower-than-expected unemployment rate and higher-than-expected inflation, sending small cap shares back down. In March, the unexpected failure of Silicon Valley Bank (SVB) had a particularly negative impact on small cap biotech, many of which were SVB clients. Even though absolute cash exposure to SVB for most biotech companies was minimal, renewed risk aversion due to the concerns over the banking system caused large cap biotech to significantly outperform small cap biotech. This trading dynamic had a particularly detrimental impact on the Company's relative performance versus the Benchmark, given that the Company is significantly overweight small cap names and underweight large cap names. The drawdown in March accounted for virtually all of the underperformance of the Company's NAV versus the Benchmark for the fiscal year. Encouragingly, the Company has seen a rebound in relative performance in April and May 2023, which we hope signals a more sustained recovery. dyor etc |
Posted at 06/5/2022 14:29 by campervan1 I was just watching the tumble weed blowing along on this board and I came across this on the ewi website. A long and interesting history, with links to James Bond!I for one will continue to hold on through this particular storm, "if necessary lashed to the wheel". |
Posted at 08/3/2021 15:11 by peterpiper313 Ocado and tesla Price dropped around 25% plus price to NAV moved from +2.7% to -7.2%.What chance of a reversal Tesla? |
Posted at 08/3/2021 15:05 by lozzer69 Looks like all BG big bets are taking a big hit. I am still sticking with them as I believe when the rotation to value settles EWI and others will return to glory. 10 pc reversal in 2 hours no showing Blue !!!! |
Posted at 21/8/2020 14:29 by uapatel “ Rolls-Royce partners with Reaction Engines for supersonic Virgin Galactic jet”The Times See that EWI hold Reaction Engines as a Unlisted company holding, around 0.4% of the portfolio. |
Posted at 13/7/2020 13:43 by peterpiper313 Has anyone any comments on whats happening to Edinburgh Worldwide IT price going through the roof? No stopping it ? Raising new shares hand over fist increasing market value and the asset value with all this new cash at a rising premium. Where will it all end? |
Posted at 21/6/2020 07:56 by poikka Yes, I forgot to mention that, but nothing compared to EWI's 4.0%. I was considering the belief in Tesla amongst fund managers - that I'm using.Whatever, Monks and EWI good growth ITs, eh. |
Posted at 20/6/2020 19:50 by poikka Very interesting interview, uapatel. I was certainly one of the naysayers regarding Tesla. Am I convinced by the story about competition being incapable of spoiling Musk's party? No, I'm not.But Ron Baron's a billionaire, and I'm merely a millionaire; however, Baron's enthusiasm still isn't so widely shared: none of my other global IT holdings - Monks, JGGI, BUT and MYI hold shares in Tesla. Whatever, EWI seems to be doing ok. |
Posted at 10/6/2020 16:49 by uapatel Poikka,Might want to watch this Ron Baron interview on CNBC regarding his view on Tesla and SpaceX. Both of which EWI and SMT hold. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions